Dr.ย Myung-Juย Ahn
MD, PhD
Professor, Medical Oncology & Thoracic Oncology
corporate_fareSamsung Medical Center, Seoul
Myung-Ju Ahn
MD, PhD
Prof. Myung-Ju Ahn is a senior thoracic medical oncologist and professor at Samsung Medical Center and Sungkyunkwan University School of Medicine in Seoul, South Korea. With more than 20 years of clinical and research experience, she is one of South Korea's most recognised experts in lung cancer precision medicine, specialising in EGFR-mutated, ALK-positive, and RET-altered non-small cell lung cancer.
Prof. Ahn's work spans the full spectrum of thoracic oncology โ from molecularly guided treatment planning in early and locally advanced disease to the management of treatment-resistant, metastatic, and CNS-involved lung cancer. She has led and participated in landmark international clinical trials evaluating targeted agents, immune checkpoint inhibitors, antibody-drug conjugates, and bispecific antibodies for NSCLC and small cell lung cancer. Her research has significantly advanced the understanding of EGFR resistance mechanisms, including MET amplification and EGFR exon 20 insertion mutations, and she is widely cited in the global lung cancer literature. International patients with complex or treatment-resistant lung cancer frequently seek her expertise for second opinions and advanced treatment planning.
CancerFax can coordinate medical-record review, consultation support, and case preparation for international patients seeking an expert opinion from Prof. Myung-Ju Ahn at Samsung Medical Center, Seoul.
Why Consider Prof. Myung-Ju Ahn?
Prof. Ahn is one of the most cited thoracic oncologists in Asia, known for her leadership in EGFR-targeted therapy research, clinical trial participation, and biomarker-driven lung cancer management.
Areas of Specialisation
Precision thoracic oncology with a focus on molecularly driven lung cancer and clinical trial-based treatment
Prof. Ahn's clinical practice focuses on evidence-based, biomarker-guided treatment for non-small cell lung cancer, small cell lung cancer, and thymic tumours. Her work emphasises molecular profiling, targeted agent sequencing, resistance pathway evaluation, and access to novel therapies through active clinical trial participation.
EGFR-Mutated Lung Cancer
Comprehensive management of EGFR-driven NSCLC, including uncommon mutations, exon 20 insertions, and resistance after osimertinib.
- arrow_rightFirst-line and subsequent EGFR TKI selection based on mutation subtype
- arrow_rightOsimertinib-based treatment strategies and post-osimertinib resistance management
- arrow_rightUncommon EGFR mutations including exon 20 insertion
- arrow_rightLiquid biopsy and tissue re-biopsy for resistance profiling
- arrow_rightMET amplification as an EGFR resistance mechanism
- arrow_rightCombination strategies targeting EGFR and MET co-alterations
ALK, RET & Other Driver Mutations
Expert management of ALK-rearranged, RET-fused, HER2-mutated, and BRAF-altered non-small cell lung cancer.
- arrow_rightNext-generation ALK inhibitor sequencing and CNS monitoring
- arrow_rightResistance assessment after first-line and subsequent ALK-directed therapy
- arrow_rightRET fusion-directed targeted therapy
- arrow_rightHER2 mutation and HER2 overexpression treatment planning
- arrow_rightBRAF V600E-altered NSCLC treatment
Immunotherapy & Antibody-Based Therapy
Clinical expertise in immune checkpoint inhibitors and emerging antibody platforms for advanced lung cancer and thymic tumours.
- arrow_rightPD-1 and PD-L1 inhibitor selection based on expression and molecular profile
- arrow_rightCombination immunotherapy and chemotherapy strategies
- arrow_rightImmunotherapy for small cell lung cancer
- arrow_rightAntibody-drug conjugates for HER2-mutated and EGFR exon 20 NSCLC
- arrow_rightBispecific T-cell engager approaches for small cell lung cancer
Small Cell Lung Cancer & Thymic Tumours
Systemic treatment and clinical trial access for SCLC and rare thoracic malignancies including thymoma and thymic carcinoma.
- arrow_rightFirst-line chemotherapy-immunotherapy combinations
- arrow_rightSecond-line and beyond systemic treatment strategies
- arrow_rightClinical trial access for novel SCLC agents
- arrow_rightThymoma and thymic carcinoma systemic treatment
- arrow_rightMultidisciplinary treatment planning with thoracic surgery and radiation oncology
Procedures Performed
Clinical services and treatment approaches in thoracic oncology
Prof. Ahn's clinical services are focused on advanced systemic treatment for lung cancer and thoracic malignancies, encompassing targeted therapy, immunotherapy, chemotherapy, and clinical trial-based approaches guided by molecular profiling.
Targeted Therapy for Lung Cancer
Targeted TherapyMolecularly guided targeted therapy for driver mutation-positive non-small cell lung cancer.
Systemic Cancer Treatment
Medical OncologyChemotherapy and immunotherapy planning and administration for lung cancer and thoracic malignancies.
Molecular Diagnostics & Staging
DiagnosisComprehensive molecular profiling and staging to guide personalised lung cancer treatment planning.
Second Opinion โ Lung Cancer
Second OpinionIndependent expert review of lung cancer diagnosis, molecular profiling, imaging, and treatment plan.
Clinical Trial Enrolment
MonitoringEvaluation and access to clinical trials for eligible patients with advanced or treatment-resistant lung cancer.
Research & Publications
Globally cited contributions to thoracic oncology and lung cancer precision medicine
Prof. Myung-Ju Ahn is one of the most prolific and globally cited researchers in lung cancer oncology. Her work spans EGFR-targeted therapy, ALK inhibitor studies, MET resistance mechanisms, small cell lung cancer immunotherapy, antibody-drug conjugates, and biomarker-driven clinical trial design.
Prof. Ahn's active clinical trial programme at Samsung Medical Center may offer eligible patients access to investigational targeted agents, immunotherapies, and antibody-based therapies not otherwise available. CancerFax can help assess trial eligibility.
Education & Training
Prof. Ahn completed her medical training and doctoral research at Sungkyunkwan University, one of South Korea's leading academic medical institutions, and has undertaken research fellowships aligned with her thoracic oncology focus.
Clinical Experience
Prof. Myung-Ju Ahn has over 20 years of clinical and research experience in thoracic oncology at Samsung Medical Center, one of South Korea's major tertiary cancer institutions. She is a professor at Sungkyunkwan University School of Medicine and holds a senior clinical position in the Division of Haemato-Oncology.
Languages & International
Prof. Myung-Ju Ahn consults in the following languages.
CancerFax can coordinate professional medical interpreter support for international patients who require assistance in languages beyond English and Korean.
CancerFax can coordinate professional medical interpreter support for patients consulting in other languages.
How CancerFax Helps You Access Dr. Myung-Ju Ahn
CancerFax is a specialist cancer patient-navigation platform. We help international patients prepare structured medical summaries, assess treatment eligibility, and connect directly with Dr. Myung-Ju Ahn's team โ with full coordination from initial inquiry to consultation.
Medical Report Review
Free review of your pathology results, imaging, molecular profiling, and treatment history โ prepared as a structured clinical summary for Dr. Myung-Ju Ahn's team.
Treatment Eligibility Screening
CancerFax screens your case for eligibility for treatments and clinical programmes available through Dr. Myung-Ju Ahn before you travel, so you arrive with a clear pathway.
Case Submission
We coordinate direct case submission to Dr. Myung-Ju Ahn's department, including all documentation required for clinical review and appointment scheduling.
Appointment & Consultation Coordination
CancerFax manages appointment scheduling with Dr. Myung-Ju Ahn's team, confirming availability and aligning timelines with your travel plans.
Travel, Visa & Logistics Support
We prepare visa invitation letters, provide hospital-proximity accommodation guidance, and coordinate airport transfers for international patients.
Follow-Up & Continuity of Care
After your consultation or treatment, CancerFax facilitates communication between Dr. Myung-Ju Ahn's team and your home oncologist for seamless post-treatment follow-up.
Frequently Asked Questions About Prof. Myung-Ju Ahn
Prof. Myung-Ju Ahn is a senior thoracic medical oncologist and professor at Samsung Medical Center and Sungkyunkwan University School of Medicine in Seoul, South Korea. She specialises in lung cancer precision medicine with a particular focus on EGFR-mutated, ALK-positive, and RET-altered non-small cell lung cancer, as well as small cell lung cancer and thymic tumours. She is widely regarded as a leading lung cancer key opinion leader in Asia.
Prof. Ahn is known for her extensive research and clinical expertise in EGFR-targeted therapy, ALK inhibitor treatment, MET-mediated resistance, EGFR exon 20 insertion lung cancer, immunotherapy for NSCLC and SCLC, antibody-drug conjugates, and bispecific antibody approaches. She is one of the most globally cited thoracic oncologists and has contributed to several landmark international clinical trials.
Yes. EGFR-mutated non-small cell lung cancer is one of Prof. Ahn's primary areas of expertise. Her work includes treatment planning for common and uncommon EGFR mutations, EGFR exon 20 insertion, osimertinib-based treatment strategies, resistance profiling including MET amplification, and combination approaches for treatment-resistant disease. She has contributed extensively to EGFR research through publications and international clinical trials.
Yes. Prof. Ahn has clinical and research expertise in ALK-positive NSCLC, including next-generation ALK inhibitor sequencing and CNS management, as well as RET-fused lung cancer and other rare driver mutations including HER2 and BRAF alterations. Her thoracic oncology programme covers the full range of molecularly targetable lung cancer subtypes.
International patients can seek consultation at Samsung Medical Center through appropriate appointment channels. Prof. Ahn consults in English and Korean. CancerFax can assist international patients with medical document preparation, structured medical summaries, appointment coordination, and treatment planning support, subject to hospital availability and case acceptance.
A second-opinion request can be submitted through CancerFax with the patient's pathology reports, IHC and NGS molecular profiling, PET-CT and CT/MRI imaging, prior treatment history with dates, and current medications. The CancerFax team will review and prepare the case for submission. The consultation format and timeline depend on the doctor's availability at Samsung Medical Center.
Patients should provide: biopsy and histopathology reports, IHC results, NGS or targeted mutation testing (EGFR, ALK, RET, MET, HER2, BRAF, PD-L1), PET-CT and CT chest imaging, MRI brain if available, prior chemotherapy, immunotherapy, or targeted therapy details with dates, recent blood tests, and discharge summaries. A liquid biopsy or ctDNA report is also useful if available.
Connect with Myung-Ju Ahn Today
Share your medical reports for a free preliminary review. Our patient coordinators will help you understand your options and arrange a direct consultation.
Medical Disclaimer: Information on this page is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making any medical decisions.